Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Larsen

Showing results (121-130 of 127) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 127 results.
European Journal of Neurology|February 8, 2005
IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosisS Wergeland, A Beiske, H Nyland, et al.
European Journal of Neurology|October 14, 2006
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's diseaseM Horstink, E Tolosa, U Bonuccelli, et al.
European Journal of Neurology|October 14, 2006
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's diseaseM Horstink, E Tolosa, U Bonuccelli, et al.
Neurology|December 11, 2002
Fluctuations in attention: PD dementia vs DLB with parkinsonismC G Ballard, D Aarsland, I McKeith, et al.
Neurology|September 25, 1998
Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysisC W Olanow, V V Myllylä, K A Sotaniemi, et al.
Neurology|September 22, 2010
Mild cognitive impairment in Parkinson disease: a multicenter pooled analysisD Aarsland, K Bronnick, C Williams-Gray, et al.
Neurology|April 2, 1999
Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple SclerosisK M Myhr, T Riise, F E Green Lilleås, et al.
Pageof 13

Showing results (121-130 of 127) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 127 results.
European Journal of Neurology|February 8, 2005
IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosisS Wergeland, A Beiske, H Nyland, et al.
European Journal of Neurology|October 14, 2006
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's diseaseM Horstink, E Tolosa, U Bonuccelli, et al.
European Journal of Neurology|October 14, 2006
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's diseaseM Horstink, E Tolosa, U Bonuccelli, et al.
Neurology|December 11, 2002
Fluctuations in attention: PD dementia vs DLB with parkinsonismC G Ballard, D Aarsland, I McKeith, et al.
Neurology|September 25, 1998
Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysisC W Olanow, V V Myllylä, K A Sotaniemi, et al.
Neurology|September 22, 2010
Mild cognitive impairment in Parkinson disease: a multicenter pooled analysisD Aarsland, K Bronnick, C Williams-Gray, et al.
Neurology|April 2, 1999
Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple SclerosisK M Myhr, T Riise, F E Green Lilleås, et al.
Pageof 13